Power Struggle at FDA: Who's in Charge?

The White House and the FDA are at odds over a staffing decision. The FDA's top boss, Marty Makary, wanted to promote Sanjula Jain-Nagpal, a policy expert. But the White House had other plans. They asked for her resignation. Makary wasn't happy about it. He pushed back. But the White House didn't back down. Jain-Nagpal is still at the FDA. That's the official word from the Department of Health and Human Services. The White House hasn't said much about it. They didn't respond to requests for comment. This isn't the first time Makary and the White House have clashed. There have been other issues with staff he's brought in. It's been a bumpy road. The Wall Street Journal reported that some officials want to scale back Makary's role. Meanwhile, the FDA has been making changes. They appointed Richard Pazdur, a veteran cancer expert, to oversee new medicine reviews. He replaced George Tidmarsh, who resigned earlier this month. There were concerns about Tidmarsh's behavior. This whole situation raises questions. Who's really in charge at the FDA? And why is there so much tension? It's a power struggle that's playing out in the headlines. And it's not clear who will come out on top.